NurrOn Pharmaceuticals Inc. is a clinical-stage biopharmaceutical company (Boston, USA) dedicated to developing novel, targeted therapeutics for the treatment of Parkinson's disease (PD) and other Nurr1-related incurable human disorders. Nurr1 is the master regulator in dopaminergic neuron development and maintenance. Based on the unique dual role of Nurr1 for development and maintenance of dopaminergic neurons and their protection from inflammation-induced death, we believe that Nurr1 can be a molecular target for paradigm changing therapeutic development for PD. ATH-399A is the leading material among Nurr1 activator candidates. The first-in-human Phase I clinical study of ATH-399A in healthy participants was completed in June 2024 and a Phase IIa trial of ATH-399A in PD patients is actively being prepared.